Cantor Fitzgerald upgraded shares of Curaleaf (OTCMKTS:CURLF) from a neutral rating to an overweight rating in a research note issued to investors on Tuesday morning, BenzingaRatingsTable reports. The firm currently has $18.00 price objective on the stock.
CURLF has been the subject of several other reports. Stifel Nicolaus started coverage on shares of Curaleaf in a research report on Wednesday, July 22nd. They issued a buy rating for the company. Roth Capital started coverage on shares of Curaleaf in a research report on Monday, June 8th. They issued a buy rating and a $9.00 target price for the company. Alliance Global Partners raised their target price on shares of Curaleaf from $12.00 to $14.00 and gave the stock a buy rating in a research report on Thursday, July 23rd. Needham & Company LLC raised their target price on shares of Curaleaf from $10.70 to $11.00 and gave the stock a buy rating in a research report on Thursday, August 6th. Finally, Canaccord Genuity reaffirmed a buy rating and issued a $15.00 target price on shares of Curaleaf in a research report on Tuesday, May 19th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $12.64.
Shares of Curaleaf stock opened at $7.97 on Tuesday. Curaleaf has a 12-month low of $2.54 and a 12-month high of $9.70. The company’s fifty day simple moving average is $7.65 and its two-hundred day simple moving average is $5.71.
Curaleaf Company Profile
Curaleaf Holdings, Inc operates as an integrated medical and wellness cannabis operator in the United States. It cultivates, processes, markets, and/or dispenses a range of cannabis products in various operating markets, including flower, pre-rolls and flower pods, dry-herb vaporizer cartridges, concentrates for vaporizing, concentrates for dabbing, tinctures, lozenges, capsules, and edibles.
Featured Article: Earnings Per Share
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.